Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors

NCT ID: NCT07259304

Last Updated: 2025-12-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-11-24

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study assesses how personal relationships (such as friendships, family relationships, or romantic partners) influence the physical activity (exercise) and well-being of young adult cancer survivors. Researchers also hope to learn how social relationships change after a cancer diagnosis, and how these changes might impact important health behaviors. The information provided may help researchers learn more about better ways to support young cancer patients in the future through interventions that help maintain good social relationships and health levels of physical activity.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. Characterize the trajectories of social health in young adult (YA) cancer patients.

II. Investigate the longitudinal associations between social health and activity behaviors in YA cancer patients.

III. Explore the effects of sociodemographic and clinical characteristics on the relationship between social health, activity behaviors, and quality of life.

OUTLINE:

Patients complete surveys over 40 minutes and wear an actigraph GT3X-BT accelerometer continuously for 7 days at baseline, 3, 6, and 12 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anatomic Stage I Breast Cancer AJCC v8 Anatomic Stage IA Breast Cancer AJCC v8 Anatomic Stage IB Breast Cancer AJCC v8 Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage IIA Breast Cancer AJCC v8 Anatomic Stage IIB Breast Cancer AJCC v8 Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IIIA Breast Cancer AJCC v8 Anatomic Stage IIIB Breast Cancer AJCC v8 Anatomic Stage IIIC Breast Cancer AJCC v8 Central Nervous System Neoplasm Clinical Stage I Cutaneous Melanoma AJCC v8 Clinical Stage IA Cutaneous Melanoma AJCC v8 Clinical Stage IB Cutaneous Melanoma AJCC v8 Clinical Stage II Cutaneous Melanoma AJCC v8 Clinical Stage IIA Cutaneous Melanoma AJCC v8 Clinical Stage IIB Cutaneous Melanoma AJCC v8 Clinical Stage IIC Cutaneous Melanoma AJCC v8 Clinical Stage III Cutaneous Melanoma AJCC v8 Hodgkin Lymphoma Malignant Bone Neoplasm Malignant Brain Neoplasm Malignant Solid Neoplasm Malignant Testicular Neoplasm Non-Hodgkin Lymphoma Pathologic Stage I Cutaneous Melanoma AJCC v8 Pathologic Stage IA Cutaneous Melanoma AJCC v8 Pathologic Stage IB Cutaneous Melanoma AJCC v8 Pathologic Stage II Cutaneous Melanoma AJCC v8 Pathologic Stage IIA Cutaneous Melanoma AJCC v8 Pathologic Stage IIB Cutaneous Melanoma AJCC v8 Pathologic Stage IIC Cutaneous Melanoma AJCC v8 Pathologic Stage III Cutaneous Melanoma AJCC v8 Pathologic Stage IIIA Cutaneous Melanoma AJCC v8 Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 Pathologic Stage IIID Cutaneous Melanoma AJCC v8 Prognostic Stage I Breast Cancer AJCC v8 Prognostic Stage IA Breast Cancer AJCC v8 Prognostic Stage IB Breast Cancer AJCC v8 Prognostic Stage II Breast Cancer AJCC v8 Prognostic Stage IIA Breast Cancer AJCC v8 Prognostic Stage IIB Breast Cancer AJCC v8 Prognostic Stage III Breast Cancer AJCC v8 Prognostic Stage IIIA Breast Cancer AJCC v8 Prognostic Stage IIIB Breast Cancer AJCC v8 Prognostic Stage IIIC Breast Cancer AJCC v8 Stage I Cervical Cancer AJCC v8 Stage I Colorectal Cancer AJCC v8 Stage I Differentiated Thyroid Gland Carcinoma AJCC v8 Stage I Ovarian Cancer AJCC v8 Stage I Thyroid Gland Medullary Carcinoma AJCC v8 Stage I Uterine Corpus Cancer AJCC v8 Stage IA Cervical Cancer AJCC v8 Stage IA Ovarian Cancer AJCC v8 Stage IA Uterine Corpus Cancer AJCC v8 Stage IA1 Cervical Cancer AJCC v8 Stage IA2 Cervical Cancer AJCC v8 Stage IB Cervical Cancer AJCC v8 Stage IB Ovarian Cancer AJCC v8 Stage IB Uterine Corpus Cancer AJCC v8 Stage IB1 Cervical Cancer AJCC v8 Stage IB2 Cervical Cancer AJCC v8 Stage IC Ovarian Cancer AJCC v8 Stage II Cervical Cancer AJCC v8 Stage II Colorectal Cancer AJCC v8 Stage II Differentiated Thyroid Gland Carcinoma AJCC v8 Stage II Ovarian Cancer AJCC v8 Stage II Thyroid Gland Medullary Carcinoma AJCC v8 Stage II Uterine Corpus Cancer AJCC v8 Stage IIA Cervical Cancer AJCC v8 Stage IIA Colorectal Cancer AJCC v8 Stage IIA Ovarian Cancer AJCC v8 Stage IIA1 Cervical Cancer AJCC v8 Stage IIA2 Cervical Cancer AJCC v8 Stage IIB Cervical Cancer AJCC v8 Stage IIB Colorectal Cancer AJCC v8 Stage IIB Ovarian Cancer AJCC v8 Stage IIC Colorectal Cancer AJCC v8 Stage III Cervical Cancer AJCC v8 Stage III Colorectal Cancer AJCC v8 Stage III Differentiated Thyroid Gland Carcinoma AJCC v8 Stage III Ovarian Cancer AJCC v8 Stage III Thyroid Gland Medullary Carcinoma AJCC v8 Stage III Uterine Corpus Cancer AJCC v8 Stage IIIA Cervical Cancer AJCC v8 Stage IIIA Colorectal Cancer AJCC v8 Stage IIIA Ovarian Cancer AJCC v8 Stage IIIA Uterine Corpus Cancer AJCC v8 Stage IIIA1 Ovarian Cancer AJCC v8 Stage IIIA2 Ovarian Cancer AJCC v8 Stage IIIB Cervical Cancer AJCC v8 Stage IIIB Colorectal Cancer AJCC v8 Stage IIIB Ovarian Cancer AJCC v8 Stage IIIB Uterine Corpus Cancer AJCC v8 Stage IIIC Colorectal Cancer AJCC v8 Stage IIIC Ovarian Cancer AJCC v8 Stage IIIC Uterine Corpus Cancer AJCC v8 Stage IIIC1 Uterine Corpus Cancer AJCC v8 Stage IIIC2 Uterine Corpus Cancer AJCC v8

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Observational (actigraph, surveys)

Patients complete surveys and wear an actigraph GT3X-BT accelerometer continuously for 7 days at baseline, 3, 6, and 12 months.

Medical Device Usage and Evaluation

Intervention Type OTHER

Wear an actigraph GT3X-BT accelerometer

Quality-of-Life Assessment

Intervention Type OTHER

Complete survey

Survey Administration

Intervention Type OTHER

Complete survey

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Medical Device Usage and Evaluation

Wear an actigraph GT3X-BT accelerometer

Intervention Type OTHER

Quality-of-Life Assessment

Complete survey

Intervention Type OTHER

Survey Administration

Complete survey

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Quality of Life Assessment

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed and/or treated with cancer between ages 18-39 at USC hospitals.
* Cancer types prototypical for adolescents and young adults (AYAs) and cancer stages I-III; select patients with stage IV disease may be eligible, with approval by the principal investigator (PI) and in consultation with the treating clinician.
* Must be within three months of a de novo cancer diagnosis at recruitment and on/indicated for curative therapy (any modality). Patients may continue on adjuvant therapy throughout duration of the study.
* Patients must have anticipated survival of \>1-year at time of diagnosis.

Exclusion Criteria

* Diagnosis of blood malignancies such as leukemias (these cancers have divergent treatment patterns of longer duration than other cancers and are more commonly pediatric cancers). Some early stage lymphomas with favorable prognoses may be eligible, with approval by the PI and in consultation with the treating clinician.
* Primary language other than English or Spanish.
* Inability to complete a survey and/or wear an accelerometer either per the patient or in consultation with the clinician's judgment.
Minimum Eligible Age

18 Years

Maximum Eligible Age

39 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cancer Institute (NCI)

NIH

Sponsor Role collaborator

University of Southern California

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kimberly Miller, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Southern California

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

USC / Norris Comprehensive Cancer Center

Los Angeles, California, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kimberly A Miller, PhD

Role: CONTACT

323-865-0674

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kimberly Miller

Role: primary

323-865-0674

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCI-2021-05723

Identifier Type: REGISTRY

Identifier Source: secondary_id

0S-20-10

Identifier Type: OTHER

Identifier Source: secondary_id

P30CA014089

Identifier Type: NIH

Identifier Source: secondary_id

View Link

R37CA256867

Identifier Type: NIH

Identifier Source: secondary_id

View Link

0S-20-10

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.